To view video, and read the full article visit URL http://crweselect.com/27742/stock-alerts/rvsn-oxgn-fcel-crweselectcom-st...
Radvision Ltd. (NASDAQ:RVSN)
RVSN announced today that GP Synergy, a leading provider of general practice education and training, delivering training across Sydney and northwest NSW, has implemented RADVISION's premier video collaboration technology to further the reach of its educational training services. GP Synergy is leveraging RADVISION's high definition (HD) desktop video systems and infrastructure for administrative and board meetings. Participants can connect to calls hosted on a RADVISION SCOPIA MCU using customized GP Synergy-provided systems, comprised of a unique combination of RADVISION's SCOPIA VC240 and SCOPIA Desktop systems. Additionally, remote participants can join the video calls using their laptops over a Wi-Fi or 3G/4G connection.
Founded in 1992, RVSN is a leading provider of videoconferencing and telepresence technologies over IP and wireless networks. RADVISION teams with its channel and service provider partners to offer end-to-end visual communications that help businesses collaborate more efficiently. RADVISION propels the unified communications evolution forward with unique technologies that harness the power of video, voice, and data over any network.
For more information about RVSN please visit http://www.radvision.com
OXiGENE, Inc. (NASDAQ:OXGN)
OXGN and Azanta Danmark A/S, a specialty pharmaceutical company focused on oncology, women's health and addiction medicine, have established a partnership agreement to provide access to ZYBRESTAT for the treatment of patients in Europe and Canada with anaplastic thyroid cancer (ATC) on a compassionate use basis. OXiGENE's newly-formed Named Patient Program (NPP), to be managed by Azanta, provides a regulatory mechanism to allow healthcare professionals in Europe and Canada to prescribe ZYBRESTAT to individual ATC patients while it is still in development.
OXGN is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. The Company's major focus is developing vascular disrupting agents that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.
For more information about OXGN please visit http://www.oxigene.com/
FuelCell Energy, Inc. (NASDAQ:FCEL)
FCEL announced today a partnership agreement with Abengoa S.A. to develop localized stationary fuel cell power plants for markets in Europe and Latin America. Abengoa will develop, manufacture and market stationary fuel cell power plants using fuel cell modules provided by FuelCell Energy. The initial pilot installation will be at the Abengoa headquarters in Palmas Campus Palmas Altas, Spain using a 300 kilowatt proprietary Direct FuelCell(R) (DFC(R)) module supplied by FuelCell Energy and balance of plant designed and manufactured by Abengoa. Renewable biogas markets will be targeted and the parties will cooperate to enhance the capability and market opportunities for DFC power plants operating on liquid biofuels.
Direct FuelCell(R) power plants are generating ultra-clean, efficient and reliable power at more than 50 locations worldwide. With over 180 megawatts of power generation capacity installed or in backlog, FCEL is a global leader in providing ultra-clean baseload distributed generation to utilities, industrial operations, universities, municipal water treatment facilities, government installations and other customers around the world. The Company's power plants have generated over 900 million kWh of power using a variety of fuels including renewable biogas from wastewater treatment and food processing, as well as clean natural gas.
For more information about FCEL please visit http://www.fuelcellenergy.com/
To read the full article visit URL http://crweselect.com/27742/stock-alerts/rvsn-oxgn-fcel-crweselectcom-st...
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer( http://crweselect.com/disclaimer/) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWESelect.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.